Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 7/20 | 0.64 |
| ▸ | NPY1R | P25929 | 5/20 | 0.64 |
| ▸ | NPY2R | P49146 | 3/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.61 |
| ▸ | IL1RN | P18510 | 1/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 6/20 | 0.58 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844216 | 0.96 | NPY4R (0.67) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL29895758 | 0.94 | NPY4R (0.65) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL2184740 | 0.92 | NPY4R (0.66) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL29531691 | 0.91 | NPY4R (0.59) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL30123009 | 0.91 | NAALAD2 (0.61) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL30905993 | 0.91 | BACE1 (0.61) | BACE1BACE2 | |
| SCHEMBL31064856 | 0.91 | NAALAD2 (0.66) | NPY4RNPY1RNPY2RFOLH1BACE1 | |
| SCHEMBL29349540 | 0.90 | NAALAD2 (0.68) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL29734944 | 0.90 | FOLH1 (0.68) | NPY4RNPY1RNPY2RFOLH1IL1RN | |
| SCHEMBL29822390 | 0.90 | FOLH1 (0.68) | NPY4RNPY1RNPY2RFOLH1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | NPY4R 567/4885NPY1R 544/4885NPY2R 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.